An announcement from JDRF this morning gave us the news I’d been hoping for: Come the 1st of October (only a few weeks away) Fiasp Penfills will become available via PBS scripts. This is the outcome I had been expecting/hoping for based on scuttlebutt. Prescriptions will come with 1 repeat. Each fill of the script …
Announced today at ADATS, the LibreLink software will be updated soon in Australia. There are two major features: It will use the Libre 2 sensors (which do not need updates for this) to turn LibreLink into a realtime CGM app. No need to scan your sensor to get readings. It will receive a new setting …
Significant LibreLink update coming to Australia Read More »
Next week I’m lucky enough to be heading off to San Diego to attend the American Diabetes Association’s annual conference: the ADA Scientific Sessions. I’m attending as part of the #dedoc˚ voices program, as one of 12 diabetes advocates from around the globe who together will be trying to represent people who live with diabetes …
I wrote recently about re-usable pens (which I much prefer over the disposables). For years in Australia Novo Nordisk has provided two pens to use with their Penfill cartridges: NovoPen 4: 1U increments up to 60U/dose. NovoPen Echo: has memory of last dose size and time, 0.5U increments up to 30U. Of course, the older NovoPen …
In the last article I discussed what I think is a remarkable comparison between my recent personal data and the output of a 2019 CGM study of people without diabetes. At the end I showed a graph stretching over 20 years. It shows my HbA1c results over that time, overlaid with the TIR data from …
Further comparison with HCL and non-diabetic data Read More »
I’ve written multiple times about the benefits of using different ranges for Time In Range (see “Targets and Goals“). This is revisiting that topic in light of some recent experimental data. Like many this article has become quite long, but it’s split into sections: Terminology introduction, and choosing a new range based on published study …